hPD-1(3)
Nomenclature
C57BL/6JSmo-Pdcd1tm2(hPDCD1)Smoc
Cat. NO.
NM-HU-235087
Strain State
Repository Live
Gene Summary
Gene Symbol
Pdcd1
Model Description
Validation Data

Fig.1 Detection of PDCD1 expression in spleen by RT-PCR. Spleen RNA was extracted from 7-week-old female wild-type C57BL/6 (WT)(n=2) and homozygous hPD-1(3) knockin mice (HO) (n=2), then cDNA libraries were synthesized by reverse transcription, followed by PCR with mRNA primers. Mouse Pdcd1 mRNA (187 bp) was detectable only in wild-type C57BL/6 mice. Human PDCD1 mRNA (137 bp) was detectable only in homozygous hPD-1(3) knockin mice but not in wild-type mice.

Fig.2 Detection of PDCD1 expression in spleen by qPCR. H/M Pdcd1 mRNA was detectable both in wild-type mice and homozygous hPD-1(3) knockin mice. Spleen RNA was extracted from 7-week-old female wild-type C57BL/6 (WT)(n=2) and homozygous hPD-1(3) knockin mice (HO) (n=2), then cDNA libraries were synthesized by reverse transcription, followed by qPCR with h/m Pdcd1 and mouse Gapdh primers. Relative expression represents the h/m Pdcd1 mRNA level relative to its average expression in homozygous hPD-1(3) knockin mice.

Fig.3 Human and mouse PD-1 expression on T cells from WT C57BL/6 and HO hPD-1 homozygous mice. Splenocytes were gated on CD3⁺ or CD4⁺ T cells and analyzed by flow cytometry with anti-human PD-1and anti-mouse PD-1. Flow cytometric analysis shows that human PD‑1 is expressed on CD3⁺ and CD4⁺ T cells in HOhPD-1 mice , while WT C57BL/6 mice lack human PD‑1 expression, confirming successful humanization of the Pdcd1 locus.
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreSMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn more